Headlines about Biogen (NASDAQ:BIIB) have trended somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biogen earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.887072399643 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern’s analysis:
- Biogen, Ionis Sink After Company Announces Rival To Spinraza (finance.yahoo.com)
- Mufg Americas Holdings Has Cut Biogen (BIIB) Stake By $3.66 Million; Shorts at Globalscape (NYSEAMERICAN:GSB … – Hill Country Times (hillcountrytimes.com)
- Biogen Inc. (BIIB) – Well known Mover to Watch – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Brokerages Expect Biogen Inc (BIIB) Will Post Quarterly Sales of $3.05 Billion (americanbankingnews.com)
- Biogen Inc (BIIB) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
BIIB has been the topic of a number of recent research reports. Goldman Sachs Group upgraded shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 target price on the stock in a research note on Wednesday, August 16th. Vetr upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $319.53 target price on the stock in a research note on Thursday, August 17th. Robert W. Baird restated a “hold” rating and set a $290.00 target price on shares of Biogen in a research note on Friday, August 25th. ValuEngine downgraded Biogen from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Mizuho reaffirmed a “neutral” rating and issued a $319.00 price target (up from $274.00) on shares of Biogen in a report on Wednesday, September 13th. Twelve research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Biogen presently has an average rating of “Buy” and a consensus target price of $344.60.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $5.70 by $0.61. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the company earned $5.19 earnings per share. equities research analysts expect that Biogen will post 22.03 EPS for the current fiscal year.
In other news, Director Alexander J. Denner acquired 30,000 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the completion of the acquisition, the director now owns 10,029 shares of the company’s stock, valued at $3,182,803.44. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.25% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Biogen (BIIB) Receiving Somewhat Favorable News Coverage, Analysis Finds” was first published by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://weekherald.com/2017/12/14/biogen-biib-receiving-somewhat-favorable-news-coverage-analysis-finds.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.